Translating Immuno-Oncology into Health Actions
Cancer immunotherapy focused public-private collaborative for better research, innovation, health care and public awareness
Cancer IO is a cancer immunotherapy focused top-level collaborative research and innovation project that starts as a part of the Business Finland’s Personalized Health Program.
Cancer IO is a University of Helsinki coordinated project that integrates immuno-oncology (IO) activities at the Universities of Helsinki and Turku, 4 University hospitals and one central hospital, 11 Finnish small or medium enterprises, 3 cancer patient organizations and the 10 largest IO-investing pharmaceutical companies.
News & updates
“Single-cell tumor immunity” Sebinar recording is now available!
Welcome to watch the recording of the Cancer IO Sebinar “Single-cell tumor immunity”.
Cancer IO’s new report: Cancer Clinical Trials - Preparedness in Finnish Hospitals
The report, published on 16 September 2021, describes the hospital preparedness for cancer clinical trials in Finland.
“Next-gen immunotherapies: Innate immunity” sebinar recording now available!
Welcome to watch a recording of our second Sebinar! This time we hear about the latest developments in the “next-gen” immunotherapies (post-immune checkpoint blockade) in the form of new therapies targeting the innate immune system.
